Efficiency of Orexin-A for Inflammatory Flare and Mucosal Healing in Experimental Colitis: Comparison with the Anti-TNF Alpha Infliximab
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24119554 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Anne Blais und 5 weiteren Autor:innen. Beteiligte Einrichtung: UMR-PNCA, Université Paris-Saclay, AgroParisTech, INRAE, 91120 Palaiseau, France. Hauptthemen laut MEDLINE: Colitis, Colitis, Ulcerative. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sandoz Novartis.
Abstract (Originalsprache)
Inflammatory bowel diseases are chronic inflammation of the intestinal mucosa characterized by relapsing–remitting cycle periods of variable duration. Infliximab (IFX) was the first monoclonal antibody used for the treatment of Crohn’s disease and ulcerative colitis (UC). High variability between treated patients and loss of IFX efficiency over time support the further development of drug therapy. An innovative approach has been suggested based on the presence of orexin receptor (OX1R) in the inflamed human epithelium of UC patients. In that context, the aim of this study was to compare, in a mouse model of chemically induced colitis, the efficacy of IFX compared to the hypothalamic peptide orexin-A (OxA). C57BL/6 mice received 3.5% dextran sodium sulfate (DSS) in drinking water for 5 days. Since the inflammatory flare was maximal at day 7, IFX or OxA was administered based on a curative perspective at that time for 4 days using intraperitoneal injection. Treatment with OxA promoted mucosal healing and decreased colonic myeloperoxidase activity, circulating concentrations of lipopolysaccharide-binding protein, IL-6 and tumor necrosis factor alpha (TNFα) and decreased expression of genes encoding cytokines in colonic tissues with better efficacy than IFX allowing for more rapid re-epithelization. This study demonstrates the comparable anti-inflammatory properties of OxA and IFX and shows that OxA is efficient in promoting mucosal healing, suggesting that OxA treatment is a promising new biotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UMR-PNCA, Université Paris-Saclay, AgroParisTech, INRAE, 91120 Palaiseau, France.
- Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, 93000 Bobigny, France.
- INSERM UMR 1149/Centre de Recherche sur l'Inflammation (CRI), Faculté de Médecine X. Bichat, Université Paris Cité, 75018 Paris, France.
ORCID-Profile: Anne Blais, François Blachier, Alain Couvineau
Förderung
- Sandoz Novartis
Zitieren
APA
Blais, A., Lan, A., Blachier, F., Benamouzig, R., Jouet, P., & Couvineau, A. (2023). Efficiency of Orexin-A for Inflammatory Flare and Mucosal Healing in Experimental Colitis: Comparison with the Anti-TNF Alpha Infliximab. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119554
Vancouver
Blais A, Lan A, Blachier F, Benamouzig R, Jouet P, Couvineau A. Efficiency of Orexin-A for Inflammatory Flare and Mucosal Healing in Experimental Colitis: Comparison with the Anti-TNF Alpha Infliximab. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24119554
BibTeX
@article{Blais2023,
author = {Blais, Anne and Lan, Annaïg and Blachier, François and Benamouzig, Robert and Jouet, Pauline and Couvineau, Alain},
title = {Efficiency of Orexin-A for Inflammatory Flare and Mucosal Healing in Experimental Colitis: Comparison with the Anti-TNF Alpha Infliximab},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24119554}
}
EUVIMED